# FORM 3

### UNITED STATES SECURITIES AND EXCHANGE **COMMISSION**

Washington, D.C. 20549

#### OMB 3235-Number: Estimated average burden hours per response...

OMB APPROVAL

0104

0.5

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| (Print or Type Responses)                       |   |   |   |   |   |                          |   |   |  |  |
|---|---|---|---|---|---|--------------------------|---|---|--|--|
| 1. Name and Address of Reporting 2. Date of Evo |   |   | ent Requiring 3. Issuer Name and Ticker or Trading Symbol |   |   |                          |   |   |  |  |
| Person – Opko Health, Inc.                      | erson * Statement Onko Health Inc (Month/Day/ |   |   | VBI Vaccines Inc/BC [VBIV]                                |   |                          |   |   |  |  |
| (Last) (First) (Midd                            | 01/01/20                                      | 017                                     |   | 4. Relationsh<br>Person(s) to 1                           | ip of Reportin  |                          |   | 5. If Amendment, Date Original Filed(Month/Day/Year)        |  |  |
| (Street) MIAMI, FL 33137                        |   |   |   | Director  | Officer (give Other (specify  |                          | 6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person |   |  |  |
| (City) (State) (Zi                              | p)  | Tal                                     | ole I   | - Non-Derivati  | ive Securiti  | ities Beneficially Owned |   |   |  |  |
| 1.Title of Security<br>(Instr. 4)               |   | Ben                                     |   | nt of Securities<br>Ily Owned                             | 3.<br>Ownership<br>Form: Direct<br>(D) or<br>Indirect (I)<br>(Instr. 5) | Owne                     | rship   | lirect Beneficial   |  |  |
| Common Stock                                    | Common Stock                                  |   |   | 5,023,014 <u>(1)</u>                                      |   |                          |   |   |  |  |
| not required number.                            | o respond to t<br>I to respond ui             | he colle<br>nless th                    | ectior<br>ne for  | n of information<br>rm displays a c                       | n contained<br>urrently vali  | in this<br>d OME         | 3 control   |   |  |  |
| 1. Title of Derivative Security (Instr. 4)      | 2. Date Exercis                               | 2. Date Exercisable and Expiration Date |   | tle and Amount of rities Underlying vative Security r. 4) |   | 5.<br>On Ow<br>se For    | vnership<br>rm of<br>rivative   | 6. Nature of Indirect<br>Beneficial Ownership<br>(Instr. 5) |  |  |
|   | Date Ex<br>Exercisable Da                     |   |   | Amount or Num<br>of Shares                                | Derivativ<br>Security   | Din<br>or (I)            | curity:<br>rect (D)<br>Indirect<br>str. 5)  |   |  |  |
| Reporting Owners                                | 3   |   |   |   |   |                          |   |   |  |  |
| Reporting Owner Name / Addres                   | SS Director 10%                               | Owner (                                 | _   | or Other  |   |                          |   |   |  |  |
| 0 1 77 11 7                                     |   |   |   |   |   |                          |   |   |  |  |

| Paparting Owner Name / Address | Relationships |           |         |       |  |  |
|--------------------------------|---------------|-----------|---------|-------|--|--|
| Reporting Owner Name / Address | Director      | 10% Owner | Officer | Other |  |  |
| Opko Health, Inc.              |               |           |         |       |  |  |
| 4400 BISCAYNE BLVD.            |               | X         |         |       |  |  |
| MIAMI, FL 33137                |               |           |         |       |  |  |

## **Signatures**

| Adam Logal, Senior Vice President, CFO | 11/09/2017 |
|--|------------|
| Signature of Reporting Person          | Date       |

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). In June 2012, OPKO acquired a 50% stock ownership in SciVac Ltd., a privately held Israeli corporation ("Old SciVac"). In July 2015, Old SciVac completed a reverse takeover (the "Transaction") of Levon Resources Ltd., a Canadian corporation and Levon changed its name to "SciVac Therapeutics Inc." ("SciVac"). At the time the Transaction became effective, OPKO's Old SciVac Shares were
- (1) exchanged for 185,129,317 common shares of SciVac, and OPKO became the beneficial owner of approximately 24.5% of SciVac.
  SciVac acquired VBI Vaccines (Delaware) Inc., a Delaware corporation in May 2016, and changed its name to "VBI Vaccines Inc."
  Subsequently in 2016, OPKO participated in a private placement of VBI shares and also received additional shares of VBI in connection with an anti-dilution clause with respect to the merger in 2016. OPKO's percentage ownership was then approximately 15.1%. At the time of these transactions, the issuer was a foreign private issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.